CytomX Therapeutics, Inc.
CTMX
$2.32
$0.219.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 147.56M | 138.10M | 126.62M | 119.57M | 119.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 147.56M | 138.10M | 126.62M | 119.57M | 119.18M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 147.56M | 138.10M | 126.62M | 119.57M | 119.18M |
| SG&A Expenses | 31.40M | 29.73M | 31.93M | 30.79M | 29.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.60M | 113.11M | 119.91M | 113.85M | 108.35M |
| Operating Income | 35.96M | 25.00M | 6.71M | 5.72M | 10.83M |
| Income Before Tax | 41.84M | 32.09M | 15.06M | 15.08M | 20.47M |
| Income Tax Expenses | 236.00K | 223.00K | 1.23M | 3.99M | 3.94M |
| Earnings from Continuing Operations | 41.60 | 31.87 | 13.83 | 11.09 | 16.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.60M | 31.87M | 13.83M | 11.09M | 16.53M |
| EBIT | 35.96M | 25.00M | 6.71M | 5.72M | 10.83M |
| EBITDA | 37.65M | 26.76M | 8.55M | 7.62M | 12.87M |
| EPS Basic | 0.48 | 0.38 | 0.17 | 0.14 | 0.20 |
| Normalized Basic EPS | 0.30 | 0.24 | 0.11 | 0.12 | 0.15 |
| EPS Diluted | 0.48 | 0.38 | 0.16 | 0.13 | 0.19 |
| Normalized Diluted EPS | 0.30 | 0.24 | 0.11 | 0.12 | 0.15 |
| Average Basic Shares Outstanding | 342.84M | 337.75M | 333.56M | 329.20M | 310.85M |
| Average Diluted Shares Outstanding | 342.98M | 338.46M | 334.27M | 330.06M | 311.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |